Page 116 - Read Online

Hochhalter et al. Association between HCMV and GBM

NLM Identifier: NCT02529072. [Last accessed on 2017 Feb 22] Lymphopenia Using Cytomegalovirus-specific T-cell Adoptive
84. Medicine BCo. Administration of HER2 Chimeric Antigen Receptor Transfer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National
Expressing CMV-Specific Cytotoxic T Cells Ins Patients With Library of Medicine (US); 2000. Available from: http://clinicaltrials.
Glioblastoma Multiforme (HERT-GBM). In: ClinicalTrials.gov gov/show/NCT00693095 NLM Identifier: NCT00693095. [Last
[Internet]. Bethesda (MD): National Library of Medicine (US); 2000. accessed on 2017 Feb 22]
Available from: http://clinicaltrials.gov/show/NCT01109095 NLM 88. Hospital KU. A Randomized Double Blind Controlled Proof of
Identifier: NCT01109095. [Last accessed on 2017 Feb 22] Concept Study of the Efficacy and Safety of Valcyte® as an Add-on
85. John Sampson DUMC. REGULATory T-Cell Inhibition With Therapy in Patients With Malignant Glioblastoma With Successful
Basiliximab (Simulect®) During Recovery From Therapeutic Surgical Resection of at Least 90 % of the Initial Tumor and CMV
Temozolomide-induced Lymphopenia During Antitumor Infection Demonstrated Histologically and Immunohistochemically.
Immunotherapy Targeted Against Cytomegalovirus in Patients With In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of
Newly-Diagnosed Glioblastoma Multiforme. In: ClinicalTrials.gov
[Internet]. Bethesda (MD): National Library of Medicine (US); 2000. Medicine (US); 2000. Available from: http://clinicaltrials.gov/show/
Available from: http://clinicaltrials.gov/show/NCT00626483 NLM NCT00400322 NLM Identifier: NCT00400322. [Last accessed on
Identifier: NCT00626483. [Last accessed on 2017 Feb 22] 2017 Feb 22]
86. John Sampson DUMC. Anti-Tumor Immunotherapy Targeted Against 89. Wick W, Wick A, Platten M. Good maths is needed to understand
Cytomegalovirus in Patients With Newly-Diagnosed Glioblastoma CMV data in glioblastoma. Int J Cancer 2014;134:2991-2.
Multiforme During Recovery From Therapeutic Temozolomide- 90. Mitchell DA, Batich KA, Gunn MD, Huang MN, Sanchez-Perez L,
induced Lymphopenia. In: ClinicalTrials.gov [Internet]. Bethesda Nair SK, Congdon KL, Reap EA, Archer GE, Desjardins A, Friedman
(MD): National Library of Medicine (US); 2000. Available from: AH, Friedman HS, Herndon JE 2nd, Coan A, McLendon RE, Reardon
http://clinicaltrials.gov/show/NCT00639639 NLM Identifier: DA, Vredenburgh JJ, Bigner DD, Sampson JH. Tetanus toxoid and
NCT00639639. [Last accessed on 2017 Feb 22] CCL3 improve DC vaccines in mice and glioblastoma patients.
87. John Sampson DUMC. Evaluation of Recovery From Drug-Induced Nature 2015;519:366-9.

108 Neuroimmunology and Neuroinflammation ¦ Volume 4 ¦ June 16, 2017